Orforglipron Tracker — How the Non-Peptide GLP-1 Pill Works

You've read the headlines: a GLP-1 pill with no fasting rules. Then you open a trial paper and the doses say 36 mg, while the bottle in your hand says 17.2 mg. Before you start logging anything, it helps to know what orforglipron actually is, and why its numbers look the way they do.

What makes orforglipron different from other GLP-1 medicines?

Most GLP-1 medicines, including semaglutide and tirzepatide, are peptides: chains of amino acids built to resemble the body's own hormones. Peptides are fragile in the gut, which is why most are injected, and why the semaglutide tablet needs an absorption enhancer called SNAC plus a strict empty-stomach routine.

Orforglipron is a small molecule, not a peptide. It binds to and activates the same human GLP-1 receptor, which the label describes as a regulator of appetite and food intake. But it's built more like a conventional pill.

One quirk follows from that. Orforglipron isn't active at the rat and mouse GLP-1 receptor, so the rodent thyroid tumors seen with other GLP-1 medicines couldn't be tested the same way. The label still carries the class's boxed thyroid warning.

Why can it be taken with food?

The label reports no clinically relevant food effect. In a study with an investigational tablet, taking it with food lowered total exposure by about 19%, which the label didn't consider meaningful. So the instructions are simply once daily, with or without food, swallowed whole.

That changes what's worth logging. With the semaglutide tablet, the clock around the tablet is part of the dose. With orforglipron, the main thing is that the tablet went down at all, each day.

How long does it stay in the body?

The label gives a half-life of 29 to 49 hours. Blood levels peak 4 to 8 hours after a dose and reach a steady state in about a week.

Two practical things follow. A new dose step takes several days to fully settle, so the first week of a step is a sensible window to watch closely. And because orforglipron is cleared mainly by the liver enzyme CYP3A4, other medicines can push its levels up or down. In one study, clarithromycin raised exposure about 3.5-fold and carbamazepine cut it by 82%. Your medicine list belongs in your log.

What did the trials find?

The label rests on two 72-week, placebo-controlled trials, both alongside diet and activity coaching. The first was published in the New England Journal of Medicine as ATTAIN-1.

Average weight change at 72 weeks	Placebo	5.5 mg	9 mg	17.2 mg
Adults without diabetes (3,127 people)	−2.1%	−7.4%	−8.3%	−11.1%
Adults with type 2 diabetes (1,613 people)	−2.5%	−5.1%	−7.0%	−9.6%

In the diabetes trial, HbA1c fell by 1.7 points at 17.2 mg, versus 0.4 on placebo. The label also reports bigger falls in waist size, systolic blood pressure and triglycerides than on placebo. These are group averages; individual results ranged widely.

Is it approved for diabetes?

Not yet in the US label. The July 2026 label covers weight reduction in adults with obesity, or overweight plus a weight-related condition, sold as Foundayo. If you're in an orforglipron diabetes study, your study team's instructions come first. Our Foundayo tracker covers the day-to-day routine with the brand-name tablet.

What we'd track

Knowing how orforglipron behaves points to a slightly different log:

1. Each daily tablet, and its strength as printed. Tablet strengths and trial capsule doses don't line up, so record exactly what's on the label.
2. The date of every step. Steady state takes about a week, so it helps to see side effects against the start of each step.
3. New or stopped medicines. CYP3A4 interactions can change your orforglipron levels; note any change and tell your prescriber.
4. Stomach symptoms, rated daily. The label says nausea, vomiting and diarrhea were most common while doses were going up.
5. Weight and waist, weekly. Trials measured both, and a weekly trend is calmer than a daily one.

Holt logs daily pills as well as weekly shots, with reminders, a lock-screen Live Activity, side-effect sliders lined up against your dose history, and Apple Health sync for weigh-ins. It's free to download, with an optional subscription.

Log orforglipron doses and steps in Holt